Thymosin alpha-1: approved abroad, gray here, and the immune evidence
Last updated: October 28, 2026 · 8 min read · By the Grey Peptides Editorial Board
- Thymosin alpha-1 was approved in over 35 countries by a 2009 count, for hepatitis B and C and as an immune stimulant, but it is not approved in the US.
- Its largest trial, a placebo-controlled study of 1,106 people with sepsis, found no survival benefit.
- In 2024, FDA's compounding advisers voted 4 to 17 against adding it to the list of substances pharmacies may compound; FDA cites immunogenicity and impurity concerns.
- It is a different molecule from TB-500, despite the shared 'thymosin' name; WADA lists TB-500 as a derivative of thymosin beta-4.
What thymosin alpha-1 is
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymus tissue; its drug form is called thymalfasin. A 2009 review counted approvals in over 35 countries for hepatitis B and C and as an immune stimulant and adjuvant 1; it has no US marketing approval (it is not on FDA's 503A categories list or among approved drugs) 2. A 2018 review notes that blood levels are lower than normal in hepatitis B, sepsis and several autoimmune conditions, while normal baseline levels and the best dose and schedule remain unsettled (review) 3.
The hepatitis trials: the basis of its approvals
Thymosin alpha-1's foreign approvals rest mainly on hepatitis. In a 1998 trial of 98 patients with chronic hepatitis B, complete virological response at 18 months was 40.6% after 26 weeks of treatment, 26.5% after 52 weeks and 9.4% in untreated controls; the groups had looked similar at the end of therapy (randomised trial) 4. Added to interferon in 98 HBeAg-positive patients, HBeAg loss at 72 weeks was 45.8% against 28.0% on placebo, a difference that missed statistical significance (randomised trial) 5. In hepatitis C, added to interferon in 109 patients, end-of-treatment biochemical (ALT) response was 37.1% against 16.2% on interferon alone, and sustained responses were 14.2% and 8.1% (randomised trial) 6.
These trials date from 1998 and 2006 and were small; the 1998 hepatitis C trial describes interferon as the only approved therapy at the time 6. They cannot be read as evidence for using thymosin alpha-1 today in place of current therapy.
Sepsis: a large trial and a clear null
Smaller Chinese studies had suggested benefits in sepsis: a pooled review of five trials with 198 patients reported better immune markers, lower severity scores and shorter ventilation, but not enough evidence on mortality (review) 7. The definitive test was TESTS, which randomised 1,106 adults with sepsis across 22 Chinese centres to thymosin alpha-1 or placebo every 12 hours for seven days. Twenty-eight-day mortality was 23.4% against 24.1% (hazard ratio 0.99), and no secondary or safety outcome differed (randomised trial) 8. Prespecified subgroups pointed in opposite directions, a hazard ratio of 1.67 in patients under 60 and 0.58 in those with diabetes 8; subgroup results like these generate hypotheses for new trials rather than establishing who benefits.
TESTS is the largest placebo-controlled trial in this list, and it did not confirm the smaller studies' results on survival 8.
| Condition | Best trial | Result |
|---|---|---|
| Sepsis | TESTS, 1,106 adults, 22 Chinese centres (2025) | No mortality benefit: 23.4% vs 24.1% at 28 days |
| Chronic hepatitis B | 98 patients, three arms (1998) | Complete response at 18 months 40.6% (26 weeks) vs 9.4% control |
| Hepatitis B with interferon | 98 patients, double-blind (2006) | HBeAg loss 45.8% vs 28.0%, not significant |
| Hepatitis C with interferon | 109 patients (1998) | End-of-treatment ALT response 37.1% vs 16.2% on interferon alone |
| COVID-19 | Meta-analysis of 8 studies (2023) | Lower mortality pooled, with 84% heterogeneity |
COVID-19 and other immune uses
Thymosin alpha-1 was used to treat COVID-19 in China: one Shanghai hospital gave it to 126 of 275 patients in a retrospective study that found no difference in T-cell recovery and slower viral clearance in treated patients (observational study) 9. A 2023 meta-analysis of eight studies in moderate to critical COVID-19 found lower mortality (risk ratio 0.59) but with 84% heterogeneity, no effect on ventilation or length of stay, and an effect that varied with sample size and sex (meta-analysis) 10. An open-label pilot trial of 49 hospitalised patients, against standard care, found more frequent recovery that did not reach significance and a faster CD4 rise in those on low-flow oxygen (randomised trial) 11.
Other uses remain exploratory. In dialysis patients, adding it to an H1N1 vaccine improved antibody responses in a pilot study of three groups (pilot study) 12. In 20 people with HIV and poor CD4 recovery, the CD4 share rose but the count did not change significantly at 24 weeks (single-arm study) 13. In cancer, single-arm studies combine it with chemotherapy or immunotherapy, which makes its own contribution impossible to isolate (single-arm trials) 14 15.
The US position, as of October 27, 2026
Thymosin alpha-1 is not FDA-approved. Its route to US use through compounding pharmacies has been blocked by the advisory process. The nomination to add it to the 503A bulks list, the list of substances pharmacies may compound, was withdrawn by its nominator, but FDA chose to present it to its Pharmacy Compounding Advisory Committee anyway 16. On December 4, 2024, the committee voted 4 in favour and 17 against adding thymosin alpha-1 (free base) and, separately, thymosin alpha-1 acetate to the list 17; FDA's meeting pages describe advisory committee votes as non-binding recommendations 18. FDA's presentation to the committee raised a lack of characterisation data for impurities and aggregates and the potential for immunogenicity 19.
FDA's page of bulk substances that may present significant safety risks says compounded thymosin alpha-1 may pose significant immunogenicity risk for certain routes, may have impurity and characterisation complexities, and that safety information is inadequate to understand the extent of any safety issues 20. That page lists it in its table of nominations withdrawn by the nominators, which has no date column 20. It is not on the agenda of the July 23-24, 2026 committee meeting 18 or among the five substances FDA has named for the next one, due before the end of February 2027 21, and FDA's 503A categories list (updated May 14, 2026) does not list it in any category 2. Our PCAC hub covers the 2026 process.
What FDA's reviewers found
FDA's 2024 presentation to the committee set out its reasoning. Its chemistry review concluded that both the free base and the acetate were not well characterised, noting no certificate of analysis for the free base in the nomination, no information on impurity limits, and a lack of information on aggregation when formulated for injection under the skin; it said Ta1 "may pose a significant risk for immunogenicity, potentially amplified by aggregation" 19. It cited a serum half-life of about 2 hours in healthy men after injection under the skin, and 1.9 to 3 minutes in rats given it intravenously 19. On hepatitis it reported that adding Ta1 to peginterferon was not superior to peginterferon alone in HBeAg-positive hepatitis B, and that adding it to standard care did not increase on-treatment viral response in hepatitis C 19. As of October 27, 2026 we found no final FDA decision placing thymosin alpha-1 on the 503A list.
Why the trials disagree
The positive results above come from small, often single-country or open-label studies; the one large placebo-controlled trial found no difference in mortality 8. The COVID-19 meta-analysis had 84% heterogeneity, and its mortality effect varied with study size 10. Immune markers change in several studies 13 11, but in the largest trial that did not show up as lower mortality 8.
Quality: why impurities matter for this peptide
FDA's concern about impurities is not abstract. A 2022 analysis using liquid chromatography and mass spectrometry separated and quantified 23 thymalfasin-related impurities in a Chinese Pharmacopoeia reference standard and applied the method to three commercial materials; the main impurities included deamidated and other modified forms, dimers and isomers, and over half arose directly or indirectly from the C-terminal asparagine (laboratory study) 22. Our guide to how peptides are made explains why such near-copies can matter for immune reactions.
Not the same as TB-500
The shared word 'thymosin' causes confusion. Thymosin alpha-1 is the 28-amino-acid peptide above, with approvals abroad; WADA's list names TB-500 as a derivative of thymosin beta-4, a different molecule 23. Our TB-500 entry covers that compound, and our epitalon vs thymalin page covers thymalin, which is different again.
Sport
Thymosin alpha-1 is not named on WADA's 2026 Prohibited List. Its S0 section prohibits substances not covered elsewhere on the List "with no current approval by any governmental regulatory health authority for human therapeutic use" 23; thymosin alpha-1 has been approved abroad 1, so whether S0 reaches it is a question for the athlete's anti-doping organisation. Tested athletes should seek a ruling before using it, and keep the written answer.
Questions to ask before using thymosin alpha-1
- What condition is it for, and has it been tested in that condition in a large placebo-controlled trial? For sepsis, the large trial was negative.
- Is the product an approved Zadaxin product from a country where it is licensed, or a research powder?
- Has it been tested for impurities, given FDA's concerns?
- Am I subject to anti-doping rules?
The bottom line
Thymosin alpha-1 has approvals abroad and a set of older hepatitis trials. But its largest modern trial, in sepsis, found no benefit, its COVID-19 evidence is inconsistent, and FDA's advisers voted against allowing it in compounding, citing immunogenicity and impurity concerns. In the US it remains unapproved, and neither 2026 advisory meeting includes it.
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
No. A 2009 review counted approvals in over 35 countries, for hepatitis B and C and as an immune stimulant, but it is not approved in the US.
Does thymosin alpha-1 help sepsis?
The TESTS trial of 1,106 adults found 28-day mortality of 23.4% with thymosin alpha-1 and 24.1% with placebo, no meaningful difference.
Can US pharmacies compound thymosin alpha-1?
It is not on the 503A bulks list. FDA's advisory committee voted 4 to 17 against adding it in December 2024, and FDA's safety-risks page lists immunogenicity and impurity concerns.
Is thymosin alpha-1 the same as TB-500?
No. WADA lists TB-500 as a derivative of thymosin beta-4, a different molecule.
What is Zadaxin?
A brand name for thymalfasin, the drug form of thymosin alpha-1; a 2009 review counted approvals in over 35 countries.
Related on Grey Peptides
Sources
- Goldstein, A. L., et al. (2009). From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther, 9(5), 593-608. PMID: 19392576
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories 1-3 (Updated May 14, 2026; thymosin alpha-1 not listed). Read October 27, 2026. FDA
- Pica, F., et al. (2018). Serum thymosin alpha 1 levels in normal and pathological conditions. Expert Opin Biol Ther, 18(sup1), 13-21. PMID: 30063864
- Chien, R. N., et al. (1998). Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology, 27(5), 1383-7. PMID: 9581695
- Lim, S. G., et al. (2006). A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther, 11(2), 245-53. PMID: 16640105
- Sherman, K. E., et al. (1998). Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology, 27(4), 1128-35. PMID: 9537454
- Yu, Y., et al. (2009). [Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 21(1), 21-4. PMID: 19141185
- Wu, J., et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583. PMID: 39814420
- Wang, Z., et al. (2021). Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. Front Immunol, 12, 568789. PMID: 34149679
- Soeroto, A. Y., et al. (2023). The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology, 31(6), 3317-3325. PMID: 37845598
- Shehadeh, F., et al. (2023). A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis, 227(2), 226-235. PMID: 36056913
- Carraro, G., et al. (2012). Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine, 30(6), 1170-80. PMID: 22178096
- Chen, C., et al. (2024). Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis, 24(1), 97. PMID: 38233816
- Lopez, M., et al. (1994). Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol, 5(8), 741-6. PMID: 7826907
- Xu, H., et al. (2026). Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. BMC Med, 24(1). PMID: 41749205
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, December 4, 2024 (thymosin alpha-1-related bulk drug substances; footnote: nomination withdrawn by the nominator, FDA electing to proceed). Read October 3, re-read October 27, 2026. FDA
- U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee meeting, December 4, 2024 (questions 3b and 3c, thymosin alpha-1 free base and acetate: 4 yes, 17 no each). Read October 3, re-read October 27, 2026. FDA
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda: BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, epitalon). Content current as of August 6, 2026; read October 27, 2026. FDA
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, December 4, 2024: Thymosin alpha-1 (Ta1) related bulk drug substances, FDA presentation. Read October 3, re-read October 27, 2026. FDA
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (thymosin-alpha 1, in the table of nominations withdrawn by the nominators). Content current as of April 22, 2026; read October 1, re-read October 27, 2026. FDA
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF; before the end of February 2027). Content current as of April 15, 2026; read October 27, 2026. FDA
- Cheng, Y., et al. (2022). Identification and determination of structurally related peptide impurities in thymalfasin by liquid chromatography-high-resolution mass spectrometry. Anal Bioanal Chem, 414(28), 8035-8045. PMID: 36207535
- World Anti-Doping Agency. The 2026 Prohibited List: S0 (non-approved substances) and S2.3 ("Thymosin-ß4 and its derivatives e.g. TB-500"); thymosin alpha-1 not named. Read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead